Major histocompatibility class II expression in the normal canine cornea and in canine chronic superficial keratitis.
OBJECTIVE
To compare the expression of major histocompatibility complex (MHC) class II antigen in the corneas of normal dogs and dogs affected with chronic superficial keratitis (CSK).


METHODS
MHC class II expression was determined in frozen sections of normal canine cornea and cornea from lesions of CSK by immunohistochemistry using a monoclonal antibody directed against the canine MHC class II molecule. Langerhans cell phenotype was determined morphologically and by histochemical determination of ATPase activity. To determine the influence of gamma interferon on expression of MHC class II molecules by corneal cells, corneal explants were cultured with the cytokine and MHC class II expression determined as above.


RESULTS
Numerous MHC class II-expressing cells were demonstrated within the stroma and epithelium of the normal corneal limbus and conjunctival epithelium while very little MHC class II expression was detected in the central region of normal canine cornea. In limbal and conjunctival epithelium, cells expressing MHC class II antigen showed ATPase activity, suggesting that they were Langerhans cells. Corneas from dogs with CSK showed MHC class II expression associated with stromal cells, some of which exhibited a dendritic morphology while most were lymphocytic. Corneal epithelial cells within the lesion also aberrantly expressed MHC class II. Corneal explants expressed MHC class II to varying degrees after differing periods of incubation with the cytokine gamma interferon.


CONCLUSIONS
While the normal central cornea has little MHC class II expression, aberrant expression occurs in CSK, associated with secretion of gamma interferon by infiltrating CD4-expressing lymphocytes. Although this change is likely to be a secondary feature of the CSK lesion, increased MHC class II expression may play a part in perpetuating the corneal inflammation seen in the disease.
Williams
D L
DL
Department of Clinical Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 OES, England, UK. doctordlwilliams@aol.com
D000251:Adenosine Triphosphatases / Q000378:metabolism*; D000818:Animals; D000911:Antibodies, Monoclonal; D016022:Case-Control Studies; D002908:Chronic Disease; D003315:Cornea / Q000166:cytology* / Q000378:metabolism; D004283:Dog Diseases / Q000378:metabolism* / Q000473:pathology; D004285:Dogs; D004847:Epithelial Cells / Q000166:cytology* / Q000378:metabolism; D000949:Histocompatibility Antigens Class II / Q000378:metabolism*; D007150:Immunohistochemistry / Q000662:veterinary; D007371:Interferon-gamma / Q000494:pharmacology; D007634:Keratitis / Q000378:metabolism / Q000473:pathology / Q000662:veterinary*; D007801:Langerhans Cells / Q000166:cytology* / Q000378:metabolism; D017154:Stromal Cells / Q000166:cytology / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000949:Histocompatibility Antigens Class II; D007371:Interferon-gamma; D000251:Adenosine Triphosphatases